Portugal INFARMED

Litfulo (Ritlecitinib) – Public funding evaluation report available – Approval

Original title: Litfulo (Ritlecitinib) | Relatório de avaliação de financiamento público disponível | Deferimento

INFARMED approves public funding for Litfulo (ritlecitinib) in Portugal following evaluation.

Low obligation Product class Pharmaceuticals Market Access & Reimbursement Portugal Reimbursement

Data : 13/07/2026

Dates and deadlines

Applies from

2026-07-13

Regulatory Deadline

July 13, 2026

Read the official source ↗

Published by Portugal INFARMED. HealthSignal links to the original document; the summary above is extracted from the source text.